A Chris Krueger
Overview
Explore the profile of A Chris Krueger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dietrich J, Longenecker K, Wilson N, Goess C, Panchal S, Swann S, et al.
J Med Chem
. 2020 Dec;
64(1):417-429.
PMID: 33378180
Tumor necrosis factor α (TNFα) is a soluble cytokine that is directly involved in systemic inflammation through the regulation of the intracellular NF-κB and MAPK signaling pathways. The development of...
2.
Randolph J, Li T, Krueger A, Heyman H, Chen H, Bow D, et al.
Bioorg Med Chem Lett
. 2020 Feb;
30(7):126986.
PMID: 32046903
Our HCV research program investigated novel 2'-dihalogenated nucleoside HCV polymerase inhibitors and identified compound 1, a 5'-phosphoramidate prodrug of 2'-deoxy-2'-α-bromo-β-chloro uridine. Although 1 had a favorable in vitro activity profile...
3.
Krueger A, Chen H, Randolph J, Brown B, Halvorsen G, Heyman H, et al.
Bioorg Med Chem
. 2019 Nov;
28(1):115208.
PMID: 31740203
Hepatitis C virus (HCV) nucleoside inhibitors have been a key focus of nearly 2 decades of HCV drug research due to a high barrier to drug resistance and pan-genotypic activity...
4.
Wagner R, Randolph J, Patel S, Nelson L, Matulenko M, Keddy R, et al.
J Med Chem
. 2018 Apr;
61(9):4052-4066.
PMID: 29653491
Curative interferon and ribavirin sparing treatments for hepatitis C virus (HCV)-infected patients require a combination of mechanistically orthogonal direct acting antivirals. A shared component of these treatments is usually an...
5.
Randolph J, Krueger A, Donner P, Pratt J, Liu D, Motter C, et al.
J Med Chem
. 2018 Jan;
61(3):1153-1163.
PMID: 29342358
ABT-072 is a non-nucleoside HCV NS5B polymerase inhibitor that was discovered as part of a program to identify new direct-acting antivirals (DAAs) for the treatment of HCV infection. This compound...
6.
Degoey D, Randolph J, Liu D, Pratt J, Hutchins C, Donner P, et al.
J Med Chem
. 2014 Jan;
57(5):2047-57.
PMID: 24400777
We describe here N-phenylpyrrolidine-based inhibitors of HCV NS5A with excellent potency, metabolic stability, and pharmacokinetics. Compounds with 2S,5S stereochemistry at the pyrrolidine ring provided improved genotype 1 (GT1) potency compared...
7.
Krueger A, Randolph J, Degoey D, Donner P, Flentge C, Hutchinson D, et al.
Bioorg Med Chem Lett
. 2013 May;
23(12):3487-90.
PMID: 23664214
The synthesis and structure-activity relationships of a novel aryl uracil series which contains a fused 5,6-bicyclic ring unit for HCV NS5B inhibition is described. Several analogs display replicon cell culture...
8.
Krueger A, Madigan D, Beno D, Betebenner D, Carrick R, Green B, et al.
Bioorg Med Chem Lett
. 2012 Feb;
22(6):2212-5.
PMID: 22342631
The synthesis of several pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine analogs is described with one such analog possessing subnanomolar potency in both genotype 1a and 1b cell culture HCV replicon assays.
9.
Wagner R, Larson D, Beno D, Bosse T, Darbyshire J, Gao Y, et al.
J Med Chem
. 2009 Feb;
52(6):1659-69.
PMID: 19226162
The hepatitis C virus (HCV) NS5B polymerase is essential for viral replication and has been a prime target for drug discovery research. Our efforts directed toward the discovery of HCV...
10.
Krueger A, Xu Y, Kati W, Kempf D, Maring C, McDaniel K, et al.
Bioorg Med Chem Lett
. 2008 Feb;
18(5):1692-5.
PMID: 18242993
The synthesis of several pyrrolidine inhibitor analogs is described that possess nanomolar in vitro potencies against the neuraminidase enzymes expressed by the B/Memphis/3/89 and A/N1/PR/8/34 influenza strains.